Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada

NCT ID: NCT02552849


Title
Purpose
This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and reporting observed predicted forced vital capacity (FVC) change from baseline on an ongoing basis.
Details
Conditions
Idiopathic Pulmonary Fibrosis
Keywords
Source
Hoffmann-La Roche
Sponsors
Hoffmann-La Roche
Status
Recruiting
Acronym
Last Updated
17 Jan 2017
URL
Official Link
Locations
Canada, United Kingdom